Cartesian Therapeutics, Inc. RNAC
6.88 USD -0.01 (-0.15%)
At closeNov 11, 2026, 4:00 PM EST
6.88 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
6.70 Day range 7.09
5.60 52-week range 11.00
- YTD
- -4.58%
- 1 year
- -5.75%
News
zacks.com Wall Street Analysts See a 379.63% Upside in Cartesian Therapeutics, Inc. (RNAC): Can the Stock Really Move This High? The consensus price target hints at a 379.6% upside potential for Cartesian Therapeutics, Inc. (RNAC). While empirical research shows that this sought-after metric is hardly effective, an upward…
benzinga.com Cartesian Therapeutics Q3 EPS $(0.38) Beats $(0.95) Estimate Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.95) by 60 percent. This is a 72.46 percent increase over losses of…
globenewswire.com Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027 Retreatment data for…
globenewswire.com Cartesian Therapeutics Announces New Employment Inducement Grant FREDERICK, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
seekingalpha.com Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement Cartesian Therapeutics maintains a 'Buy' rating, driven by advancing Descartes-08 cell therapy programs and imminent late-stage clinical catalysts. Topline results from the phase 3 AURORA study in…
defenseworld.net Cartesian Therapeutics (NASDAQ:RNAC) versus Syndax Pharmaceuticals (NASDAQ:SNDX) Critical Comparison Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) and Cartesian Therapeutics (NASDAQ: RNAC - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We…
globenewswire.com Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
benzinga.com HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.- benzinga.com Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.
benzinga.com Cartesian Therapeutics Presents Additional Retreatment Data Of Its Lead Investigational Asset, Descartes-08, In Patients With Generalized MG, During MGFA Scientific Session Of 2026 AANEM Annual Meeting Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatmentMedian…
globenewswire.com Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment
globenewswire.com Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
globenewswire.com Cartesian Therapeutics to Participate in Upcoming Investor Conferences FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…- benzinga.com Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
globenewswire.com Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…- benzinga.com Cartesian Therapeutics Q2 EPS $0.46 Beats $(0.86) Estimate Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $(0.86) by 153.49 percent. This is a 8 percent decrease over earnings…
globenewswire.com Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027
globenewswire.com Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
zacks.com New Strong Sell Stocks for July 1st CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.
globenewswire.com Cartesian Therapeutics Announces New Employment Inducement Grant FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
benzinga.com New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market Cartesian Therapeutics, Inc. (NASDAQ:RNAC) stock is up on Tuesday as the company is announcing a strategic licensing agreement with WestGene Biopharma.
benzinga.com New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthenia gravis trial planned for 2026.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.
benzinga.com BTIG Reiterates Buy on Cartesian Therapeutics, Maintains $44 Price Target BTIG analyst Julian Harrison reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $44 price target.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Cartesian Therapeutics Inks Licensing Agreement With Westgene Biopharma For In Vivo Chimeric Antigen Receptor T-cell Therapies In Autoimmune Diseases, For Undisclosed Upfront And Milestone Payments WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translationPlans…
globenewswire.com Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans…- benzinga.com Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
- benzinga.com Needham Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $40 Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $42 to $40.
benzinga.com Cartesian Therapeutics Announces Non-Dilutive Financing Of Up To $150M From K2 HealthVentures; Expects Topline Data From Phase 3 AURORA Trial In Q1 2027 Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that it has entered into an…
globenewswire.com Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028 Financing strengthens Cartesian's financial…
globenewswire.com Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…- benzinga.com HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $25 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $30 to $25.
globenewswire.com Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune…
benzinga.com Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.- benzinga.com Cartesian Therapeutics Q1 EPS $(1.46) Misses $(0.88) Estimate, Sales $78.000K Miss $99.833K Estimate Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.88) by 65.91 percent. This is a 114.71 percent decrease over…
- benzinga.com Wedbush Reiterates Outperform on Cartesian Therapeutics, Maintains $38 Price Target Wedbush analyst Martin Fan reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform and maintains $38 price target.
- benzinga.com Cantor Fitzgerald Upgrades Cartesian Therapeutics to Overweight, Announces $16 Price Target Cantor Fitzgerald analyst Kristen Kluska upgrades Cartesian Therapeutics (NASDAQ:RNAC) from Neutral to Overweight and announces $16 price target.
- benzinga.com Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.
benzinga.com CORRECTION: Cartesian Therapeutics Q4 Adj. EPS $(1.39) Misses $(0.85) Estimate, Sales $947.00K Beat $94.67K Estimate. Adj. EPS excludes Impairment Charges Of $56.7M Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.85) by 62.95 percent. This is a 247.5 percent decrease over…
benzinga.com Insights into Cartesian Therapeutics Q4 Earnings - benzinga.com Needham Maintains Buy on Cartesian Therapeutics, Raises Price Target to $42 Needham analyst Gil Blum maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $40 to $42.
benzinga.com Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.- benzinga.com HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Lowers Price Target to $30 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and lowers the price target from $40 to $30.
benzinga.com Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.
benzinga.com Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday - benzinga.com BTIG Maintains Buy on Cartesian Therapeutics, Raises Price Target to $44 BTIG analyst Julian Harrison maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $42 to $44.